Showing results (31-40 of 259) with videos related to
Sort By:
Pageof 26
Blood Advances|January 4, 2018
What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapySteven P Treon, Jorge J CastilloLeukemia|October 9, 2019
What is new in the treatment of Waldenstrom macroglobulinemia?Jorge J Castillo, Steven P TreonHematology/Oncology Clinics of North America|September 8, 2018
Initial Evaluation of the Patient with Waldenström MacroglobulinemiaJorge J Castillo, Steven P TreonBritish Journal of Haematology|August 21, 2019
How we manage Bing-Neel syndromeJorge J Castillo, Steven P TreonHematology. American Society of Hematology. Education Program|December 4, 2020
Management of Waldenström macroglobulinemia in 2020Jorge J Castillo, Steven P TreonHematology. American Society of Hematology. Education Program|December 10, 2017
Toward personalized treatment in Waldenström macroglobulinemiaJorge J Castillo, Steven P TreonBlood|December 25, 2013
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesisZachary R Hunter, Lian Xu, Guang Yang, et al.Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27Yangsheng Zhou, Xia Liu, Lian Xu, et al.Clinical Lymphoma & Myeloma|April 14, 2009
Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapyXavier Leleu, Jérome Tamburini, Aldo Roccaro, et al.Hematological Oncology|June 15, 2025
Diagnosis and Management of Waldenstrom's MacroglobulinemiaSteven P Treon, Shayna Sarosiek, Jorge J CastilloPageof 26